Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Autolus Therapeutics Plc ADR (NQ: AUTL ) 3.480 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jun 28, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Autolus Therapeutics Plc ADR < Previous 1 2 3 4 5 6 Next > Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors January 10, 2024 From Autolus Therapeutics plc Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's After-Market Session December 27, 2023 Via Benzinga Autolus Therapeutics Announces Changes to its Board of Directors December 22, 2023 From Autolus Therapeutics plc Via GlobeNewswire Analyst Expectations for Autolus Therapeutics's Future December 13, 2023 Via Benzinga Autolus Therapeutics PLC (NASDAQ: AUTL) Climbs to New 52-Week High November 20, 2023 Via Investor Brand Network Where Autolus Therapeutics Stands With Analysts June 02, 2023 Via Benzinga Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 December 09, 2023 From Autolus Therapeutics plc Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's Intraday Session November 28, 2023 Via Benzinga Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL) November 27, 2023 From Autolus Therapeutics plc Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's After-Market Session November 15, 2023 Via Benzinga Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023 November 15, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces participation in upcoming conferences November 06, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations November 02, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates November 02, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus October 17, 2023 From Autolus Therapeutics plc Via GlobeNewswire Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023 October 11, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023 October 11, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood September 05, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics' Obe-Cel's Shows Compelling Safety Over Gilead's Drug For Acute Lymphoblastic Leukemia August 17, 2023 Truist has raised the price target for Autolus Therapeutics PLC (NASDAQ: AUTL) from $6 to $9 Via Benzinga Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress August 03, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer July 19, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023 July 18, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia July 06, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces publication in Cancer Immunology Research June 27, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics strengthens its Board with the appointment of Dr. Robert Iannone as a Non-Executive Director June 20, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma June 16, 2023 From Autolus Therapeutics plc Via GlobeNewswire 3 Top Penny Stock Picks You Haven’t Heard Of June 14, 2023 Here are three penny stock picks investors likely haven't heard of, but probably should keep on the radar as speculative options. Via InvestorPlace Autolus to hold Annual General Meeting (AGM) of Shareholders on Friday, June 30, 2023 June 06, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO June 02, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to hold Analyst call to highlight data at ASCO from the Pivotal Phase 2 FELIX study of obe-cel data in adult r/r B-ALL May 22, 2023 From Autolus Therapeutics plc Via GlobeNewswire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.